Trial Profile

Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ublituximab (Primary)
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Acronyms ENHANCE
Sponsors TG Therapeutics Inc

Most Recent Events

30 May 2025 The protocol has been amended to addition in treatment arm and allocation is changed to randomize and masking is changed to Double blind.
30 May 2025 Planned number of patients changed from 300 to 600.
30 May 2025 According to a TG Therapeutics Inc media release, company will present data from this study at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com